Lates News

date
07/09/2025
According to AI Express, Dongwu Securities issued a research report on September 5, giving Yifeng Pharmacy (603939.SH) a "buy" rating. The main reasons for the rating include: 1) improvement in gross profit margin of various businesses and products in the first half of 2025; 2) continued optimization of store network; 3) synergistic development of online and offline channels, multi-channel support for revenue growth. (Daily Economic News)